Background: The SARS-CoV-2 pandemic impact on people with Multiple Sclerosis (pwMS) continues to worry. The disease modifying therapies in pwMS can add a more severe risk of infection when compared to the general population. Alemtuzumab is an anti-CD52 monoclonal antibody and it is one of the most immunosuppressive drugs used in Multiple Sclerosis (MS).
Case Description: We present a case of Covid-19 infection that occurred in a 24-year-old woman with MS and treated with alemtuzumab. The infection occurred 4 months after administration of the first course of alemtuzumab and had a benign course with subsequent development of antibodies. Furthermore, we present a brief review of the literature on similar published cases.
Discussion: We reviewed 17 articles concerning COVID-19 infection in MS patients in treatment with Alemtuzumab. In our case and all screened cases no severe course of disease was noted and no fatality was observed. Systematic compilation of this observation comforts clinicians about the course of Covid-19 infection despite alemtuzumab immunosuppressive treatment CONCLUSIONS: The risk of serious COVID-19 disease in MS patients treated with alemtuzumab is unknown. Physicians need to monitor carefully pwMS treated with alemtuzumab and to consider COVID-19 infection related relapse in the MS patients. Further research is recommended to evaluate the beneficial-risk profile of alemtuzumab in pandemic era.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7969858 | PMC |
http://dx.doi.org/10.1016/j.msard.2021.102908 | DOI Listing |
J Imaging Inform Med
January 2025
College of Science and Engineering, Hamad Bin Khalifa University, Ar-Rayyan, Qatar.
The advent of three-dimensional convolutional neural networks (3D CNNs) has revolutionized the detection and analysis of COVID-19 cases. As imaging technologies have advanced, 3D CNNs have emerged as a powerful tool for segmenting and classifying COVID-19 in medical images. These networks have demonstrated both high accuracy and rapid detection capabilities, making them crucial for effective COVID-19 diagnostics.
View Article and Find Full Text PDFPediatr Res
January 2025
Clinical Immunology and Vaccinology Unit, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.
Background: Recent proteomic studies have documented that Long COVID in adults is characterized by a pro-inflammatory signature with thromboinflammation. However, if similar events happen also in children with Long COVID has never been investigated.
Methods: We performed an extensive protein analysis of blood plasma from pediatric patients younger than 19 years of age Long COVID and a control group of children with acute COVID-19, MIS-C, and healthy controls resulted similar for sex distribution and age.
Sci Rep
January 2025
University Children's Hospital, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany.
During the omicron wave of the COVID-19 pandemic and with SARS-CoV-2 vaccines becoming available, seroprevalence rates rose in children and adolescents. This study investigated the impact of both SARS-CoV-2 infections and vaccinations on the incidence of acute and prolonged symptoms in real-world conditions during the transition from the pandemic to the endemic phase. Participants from a pediatric population based seroprevalence study (CorKID study) were followed up at least two and for almost four years by survey of health status features and symptoms suggestive of post-COVID syndrome (PCS).
View Article and Find Full Text PDFSci Rep
January 2025
Ph.D. Program in Global Health & Health Security, College of Public Health, Taipei Medical University, Taipei, Taiwan.
The COVID-19 pandemic may have impacted disabilities among people living with HIV; however, data on the association between COVID-19 pandemic-related healthcare disruptions and disabilities among people living with HIV is limited. We aimed to evaluate the association between COVID-19-affected HIV care behaviors and disability domains among people living with HIV in Belize. A cross-sectional study was conducted at the Western Regional Hospital and Southern Regional Hospital between August and October 2021 among people living with HIV in Belize aged ≥ 21 years and on antiretroviral therapy.
View Article and Find Full Text PDFAcad Radiol
January 2025
Department of Otolaryngology and Head and Neck Surgery, School of Medicine, Otorhinolaryngology Research Center, Guilan University of Medical Sciences, Rasht, Iran (M.H.D., S.N.). Electronic address:
Background: While many COVID-19-induced anosmia patients recover their sense of smell within a few months, a substantial number of them continue to experience olfactory impairment. In our primary study, the metabolic patterns in orbitofrontal cortex (OFC) were observed to exhibit more alterations than other regions. Hence, this study specifically probes into alterations within OFC region in subjects with persistent COVID-19-induced anosmia.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!